Vicore Pharma Holding AB (publ)

Stockholm Stock Exchange VICO.ST

Vicore Pharma Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2023: 96,558,831

Vicore Pharma Holding AB (publ) Shares (Diluted, Weighted) is 96,558,831 for the year ending December 31, 2023, a 33.71% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Vicore Pharma Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2022 was 72,214,440, a 3.64% change year over year.
  • Vicore Pharma Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2021 was 69,678,461, a 28.44% change year over year.
  • Vicore Pharma Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2020 was 54,249,185, a 26.04% change year over year.
  • Vicore Pharma Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2019 was 43,041,933, a 88.10% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
Stockholm Stock Exchange: VICO.ST

Vicore Pharma Holding AB (publ)

CEO Mr. Ahmed S. Mousa J.D.
IPO Date Dec. 10, 2015
Location Sweden
Headquarters Kronhusgatan 11
Employees 29
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.

StockViz Staff

January 15, 2025

Any question? Send us an email